Epidermal Growth Factor, Innovation and Safety

The document from 2015 reviews the therapeutic applications and safety of bioidentical recombinant human epidermal growth factor (rhEGF), highlighting its effectiveness in treating a variety of skin and mucosal conditions, including wound healing, abnormal scars, dermatitis, alopecia, hyperpigmentation, and skin aging. RhEGF has been shown to stimulate cell proliferation and migration, which aids in wound healing and may reduce recovery time. It has been tested in both humans and animal models, demonstrating optimal tolerability and safety with continuous use for months. The document also discusses the potential of rhEGF in preventing chemotherapy-induced alopecia, with studies indicating that EGF can promote hair recovery. Additionally, it references research on the development of EGF-containing products for skin improvement and wound healing. The document concludes that compounded rhEGF preparations are versatile, effective, and safe for long-term use in preventing or treating various diseases and conditions of the skin and mucosa.